ITGA9: A Potential Drug Target and Biomarker (G3680)

Target Name: ITGA9

NCBI ID: G3680

ITGA9

ITGA9: A Potential Drug Target and Biomarker

ITGA9 (Integrin alpha-9) is a protein that is expressed in many different tissues throughout the body. It is a type of transmembrane protein that is involved in many different cellular processes. ITGA9 has been identified as a potential drug target and has been shown to play a role in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overview of ITGA9

ITGA9 is a transmembrane protein that is composed of four intracellular domains: an extracellular domain, a transmembrane domain, an intracellular domain, and an optional cytoplasmic tail. It has a molecular weight of approximately 110 kDa and is expressed in many different tissues throughout the body, including the brain, heart, liver, and intestine.

The extracellular domain of ITGA9 consists of a N-terminus that is involved in protein-protein interactions and the formation of a complex with other proteins. The transmembrane domain is responsible for the protein's ability to interact with the cell membrane and for its role in signaling processes. The intracellular domain is responsible for the protein's ability to interact with intracellular signaling molecules and for its role in cellular signaling processes. The cytoplasmic tail is a region of the protein that is involved in its stability and functions as a scaffold in the cytoskeleton.

ITGA9 functions as a critical regulator of many different cellular processes, including cell adhesion, migration, and signaling pathways. It is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent the excessive migration of cells. It is also involved in the regulation of the immune response, cell signaling pathways, and cell cycle progression.

Drug targeting of ITGA9

ITGA9 has been identified as a potential drug target due to its involvement in a number of diseases. Its involvement in cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for small molecule inhibitors.

One of the most promising approaches to targeting ITGA9 is the use of small molecules that can modulate its activity. Many studies have shown that ITGA9 is sensitive to small molecules such as inhibitors of tyrosine kinase activity, which are commonly used to treat cancer and other diseases.

Another approach to targeting ITGA9 is the use of antibodies that can recognize and label it specifically. This approach has been shown to be effective in treating a variety of diseases, including cancer and neurodegenerative diseases.

ITGA9 as a biomarker

ITGA9 has also been used as a biomarker in a number of studies. Its expression has been shown to be sensitive to a variety of factors, including cancer treatment, neurodegenerative diseases, and autoimmune disorders.

One of the most promising applications of ITGA9 as a biomarker is its potential to be used as a diagnostic marker for a variety of diseases. Its expression has been shown to be sensitive to a variety of cancer treatments, including chemotherapy, radiation therapy, and targeted therapies. It has also been shown to be sensitive to the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis), which is characterized by the progressive loss of motor neurons.

In addition to its potential as a diagnostic marker, ITGA9 has also been shown to be a useful biomarker for tracking the effectiveness of neurodegenerative therapies. Its expression has been shown to be sensitive to the use of neuroprotective agents, which can help to slow the progression of neurodegenerative diseases.

Conclusion

ITGA9 is a transmembrane protein that is involved in many different cellular processes. Its expression is sensitive to a variety of factors, including cancer treatment, neurodegenerative diseases, and autoimmune disorders. As a result, ITGA9 has

Protein Name: Integrin Subunit Alpha 9

Functions: Integrin alpha-9/beta-1 (ITGA9:ITGB1) is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin

The "ITGA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets